Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: Calista Therapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS

    SBC: EnduRx Pharmaceuticals Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) or glioblastoma, is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance inthe field, and provide a desperately needed new therapy for this deadly disease. EnduRx is focused on the development of new, targeted systems f ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. IGF::OT::IGF High-Impact Substance Abuse Prevention Technologies. SBIR Phase I. Period of Performance 7/16/2014-1/15/2015

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    The overarching objective of this project is to develop an innovative technological tool that will facilitate the implementation of an evidence-based substance abuse prevention program and related health behavior risk programs among military personnel. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2014 Department of Health and Human Services
  5. IGF OT IGF A STAGE BASED MOBILE INTERVENTION FOR SUBSTANCE USE DISORDERS IN PRIMARY CARE N DA POP SEPTEMBER FEBRUARY BASE AWARD

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. IGF OT IGF VALIDATION OF MOBILE TECHNOLOGIES FOR CLINICAL ASSESSMENT

    SBC: Pro-Change Behavior Systems Inc            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. IGF OT IGF FY IWIN NAVIGATING YOUR PATH TO WELL BEING SBIR PHASE II BASE AWARD PERIOD OF PERFORMANCE

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-care immunoassay for early diagnosis of pertussis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant Pertussis is a serious and potentially life threatening respiratory disease caused by the bacterium Bordetella pertussis Worldwide million people become ill with pertussis each year and of these patients die Despite high vaccine coverage in the United States there were still over pertussis cases reported in the U S in Rapid diagn ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Role of Inter-alpha Inhibitors in Wound Healing

    SBC: PROTHERA BIOLOGICS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Wound healing is an intricately regulated process broadly characterized by phases of inflammation proliferation and remodeling Imbalances in any one of these phases can result in inadequate healing scar formation or in the development of chronic wounds such as diabetic ulcers Diabetic ulcers are responsible for the majority of lower extremity amputations ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel, Ambulatory Cuff-less Non-invasive Arterial Blood Pressure Monitor

    SBC: Krisara Engineering            Topic: NHLBI

    DESCRIPTION provided by applicant The objective of this proposal is to complete the engineering development and testing of the Non Invasive Self calibrating Ambulatory Multi Modality NISAM blood pressure device to recognize hypertensive patients not currently identified using todayandapos s technology As well as providing better management of hypertensive patients by presenting a truer roun ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government